awmsg logo



golimumab (Simponi®)


Reference No. 1562

Publication date:
05/10/2016


Appraisal information

golimumab (Simponi®) 50 mg solution for injection
golimumab (Simponi®) 100 mg solution for injection


Company: Merck Sharp & Dohme Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 20/07/2016
AWMSG meeting date: 21/09/2016
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2316
Ministerial ratification: 04/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Golimumab (Simponi®) is recommended as an option for use within NHS Wales for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti inflammatory drugs. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download